Harnessing Antifungal Cyclic Peptides to Combat Candida Auris Infections

This study investigates the potential of a cyclic peptide, [R4W4], to act as an adjuvant that enhances the efficacy of first-line antibiotics against Mycobacterium avium (M. avium). M. avium is an opportunistic nontuberculous mycobacterium (NTM) that causes pulmonary and extrapulmonary infections, particularly in immunocompromised patients and those with chronic lung disease. Traditional therapy for M. avium infections relies on prolonged courses of antibiotics such as rifampicin (RIF) and azithromycin (AZ), but rising multidrug resistance necessitates new strategies to improve host clearance of infection. The research employs THP-1 cells, a human monocyte-like cell line differentiated to model macrophage responses, to assess intracellular killing of M. avium when treated with standard antibiotics alone and in combination with the cyclic peptide [R4W4]. The study compares free and liposomal formulations of RIF and AZ, and evaluates both liposomal-encapsulated [R4W4] and liposomal combination formulations where [R4W4] is combined with the antibiotics. Colony-forming unit (CFU) counts were measured at three timepoints post-treatment—3 hours, 4 days, and 8 days—to determine short- and longer-term effects on bacterial survival within host-like cells.

The principal finding is that liposomal combination treatments pairing [R4W4] with either RIF or AZ produced a significant reduction in intracellular viability of M. avium compared to liposomal antibiotic treatment alone. Specifically, THP-1 cells treated with liposomal combination [R4W4] + RIF and liposomal combination [R4W4] + AZ showed greater decreases in CFU counts than cells treated with liposomal RIF or liposomal AZ by themselves. These results suggest that the cyclic peptide [R4W4], when delivered in liposomal combination with first-line antibiotics, can potentiate antibiotic activity against intracellular M. avium. Methodologically, the study systematically assesses various concentrations and formulations, as reflected by detailed tables outlining lipid and drug compositions, treatment combinations and concentrations, characterization of liposomal formulations, and mean CFU counts for multiple treatment conditions across timepoints. The approach addresses both formulation science—encapsulation and combination strategies—and host-pathogen interactions through a macrophage-like model. The authors conclude that liposomal combination [R4W4] is a promising adjuvant therapy to increase the susceptibility of M. avium to established antibiotics, offering a potential strategy to overcome some aspects of antimicrobial resistance in NTM infections.

Given the rising prevalence of NTM and the clinical challenge of prolonged, often ineffective therapies, strategies that boost intracellular antibiotic efficacy could shorten treatment duration, improve outcomes, and reduce the burden of refractory infection. This work provides proof-of-concept evidence supporting further preclinical development of cyclic peptide–antibiotic combination therapies and underscores the value of liposomal delivery to enhance intracellular targeting and synergy.